Werewolf Therapeutics (Werewolf Therapeutics) Debt-to-Asset : 0.29 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics Debt-to-Asset?

Werewolf Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $12.90 Mil. Werewolf Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $38.37 Mil. Werewolf Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $177.60 Mil. Werewolf Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 0.29.

Werewolf Therapeutics Debt-to-Asset Historical Data

The historical data trend for Werewolf Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics Debt-to-Asset Chart

Werewolf Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.15

0.03

0.09

0.30

Werewolf Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial													0.27	0.29	0.30	0.30	0.29

Competitive Comparison of Werewolf Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Werewolf Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Werewolf Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's Debt-to-Asset falls into.

Werewolf Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Werewolf Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(8.275	+	43.648)	/	174.833
	=	0.30

Werewolf Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(12.903	+	38.368)	/	177.6
	=	0.29

Werewolf Therapeutics (NAS:HOWL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Werewolf Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Werewolf Therapeutics (Werewolf Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472

Website

https://www.werewolftx.com

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake	officer: Chief Technology Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard	officer: Chief Operating Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc	10 percent owner	800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco	director	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin	10 percent owner	6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus	director, 10 percent owner	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin	director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520